Second life for pharma’s secret drug discovery data
Qubigen can make use of trial data without moving or copying it, saving other researchers from wild goose chases.
This is a short summary. The full story is published by Afr.
Read full story at AfrJoin PharmaJungle & connect with verified pharma buyers Register Free
Qubigen can make use of trial data without moving or copying it, saving other researchers from wild goose chases.
This is a short summary. The full story is published by Afr.
Read full story at Afr
UNLOXCYT was approved by the US Food and Drug Administration (FDA) in 2024 for adults with metastatic or locally advanced cutaneous squamous cell…

Torrent Pharmaceuticals’ Q2 FY27 net profit fell 9.6% to Rs 534 crore, although revenue rose 50.8% to Rs 4,979 crore as expenses climbed 70.9%. Dr…

Group sales rose 8% in Swiss francs to CHF 16.13 billion, and Roche kept its 2026 growth outlook.

Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years…
Get your company in front of buyers, manufacturers, and sourcing professionals on PharmaJungle - completely free for your first 30 days.
Exclusive introductory offer for new advertisers
Get offers from suppliers
Your product details and requirements may be published on the marketplace.
Fields marked with * are mandatory.